Lexaria Bioscience Corp. LEXX Archives - Page 21 of 39

ThursdayOct 27, 2022 1:21 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Successful Results of Human Clinical Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study, HYPER-H21-4, may be the first-ever study to indicate a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral cannabidiol ("CBD") therapy. The study is evaluating Lexaria's patented DehydraTECH(TM)-CBD capsule formulation. LEXX reported that study results showed exceptional safety and tolerability and statistically significant lowering of 24-hour ambulatory BP as well as BP lowered for the duration of the entire five-week study. The study also indicated lowered BP for patients currently taking other antihypertensive drugs as well…

TuesdayOct 25, 2022 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Medication Poised to Reduce Risk of Blood-Pressure-Induced Dementia, Cognitive Decline

Lexaria Bioscience is a global innovator in drug delivery platforms that has developed the patented DehydraTECH(TM) technology for improved delivery of bioactive compounds The company is currently evaluating DehydraTECH-processed CBD as a potential treatment for high blood pressure Long-term studies have shown that high blood pressure can increase the risk of developing dementia in later life Experts, however, believe that hypertension medication could slow the pace of the cognitive decline In addition to helping hypertension patients keep their condition under control, Lexaria’s DehydraTECH-CBD, which has so far been shown to be safe and well tolerated, could potentially help reduce the…

FridayOct 21, 2022 3:16 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a drug delivery platform innovator, last year announced a review of its successful 2021 antiviral drug program. “Lexaria specifically probed the bioavailability of five DehydraTECH(TM)-processed antiviral drugs for SARS-CoV-2, HIV/AIDS and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the bloodstream. The demonstrated improvements in absorption, Lexaria believed, could have significant commercial potential considering that many antiviral drugs typically show low oral bioavailability in their available form because of significant liver biotransformation and/or poor intestinal uptake,” reads a recent article. “Lexaria’s vision…

WednesdayOct 19, 2022 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Novel DehydraTECH(TM) Technology to Address Unmet Antihypertension Drug Market

Research has shown that co-occurring conditions may be linked to high blood pressure, including bone aging and mental illness The antihypertension drug market is anticipated to rise due to the launch of novel pharmaceuticals and diagnostic agents Valued at US $30.2 billion in 2021, the market is expected to grow at a CAGR of 3%, resulting in a value of US $40 billion by 2031 Lexaria’s patented DehydraTECH(TM) technology offers higher bioavailability of active pharmaceutical ingredients due to, in part, bypassing first-pass-liver processing, improving the speed of onset, and brain absorption The American Heart Association (“AMA”) refers to high blood…

MondayOct 17, 2022 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments

Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medication Reasons advanced for the suboptimal adherence include lack of awareness or treatment, increased number of prescribed medications, and major adverse effects of the prescribed drugs Lexaria has so far shown that its DehydraTECH-CBD is…

ThursdayOct 13, 2022 2:49 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients, developed the patented DehydraTECH(TM) drug delivery technology. “The company has evidenced, through in-vivo, in-vitro and pre-clinical testing, that DehydraTECH delivers more APIs at a faster rate than controls, enabling more effective drug absorption. The testing has so far involved APIs such as cannabidiol (‘CBD’), PDE5 inhibitors, antiviral drugs, and nicotine, each at different stages of product development. This DehydraTECH pipeline, Lexaria says, is addressing severe unmet patient needs. Its DehydraTECH-CBD…

ThursdayOct 13, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Patented DehydraTECH(TM) Technology to Fight America’s Silent Killer – Hypertension

Three out of four adults living with hypertension do not have the condition under control, putting them at risk for other serious complications Lexaria’s proposed therapy for hypertension is the highly efficient DehydraTECH-CBD, which has presented with no serious adverse side effects in test participants Dominated by the North American market, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026 In the United States, over 121.5 million adults are affected by high blood pressure – with statistics stacked against people of color, those with a family history of high…

TuesdayOct 11, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Offering Solutions to Growing Hypertension Problem Worldwide

Hypertension affects nearly half of all adults in the United States – 47% or 116 million people, some of which are medication-resistant A recent study from the University of Toledo College of Medicine and Life Sciences concluded gut bacteria might be the cause of medication-resistant hypertension – as demonstrated in rats used to conduct the study Lexaria’s patented DehydraTECH(TM) technology offers a viable solution for hypertension drug administration and has been received favorably by the FDA during a pre-Investigational New Drug meeting Hypertension, or high blood pressure, remains one of the world’s most deadly health problems, considered a silent killer…

FridayOct 07, 2022 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Address Declining Antihypertensive Intensification and High Prescription Abandonment Rates, with DehydraTECH-CBD

Lexaria is a global innovator in drug delivery platforms developing DehydraTECH-CBD as a potential treatment for hypertension A 2022 study documented a decline in the percentage of patients receiving appropriate treatment intensification over the last ten years This decline has been attributed to, among other possible reasons, the side effects of antihypertensive drugs At the same time, only 24% of adults with hypertension have the condition under control, a statistic attributable to the medications’ troublesome side effects Lexaria’s investigations of its DehydraTECH-CBD have so far presented favorable safety and tolerability data, meaning its drug candidate could offer reprieve to millions…

ThursdayOct 06, 2022 2:14 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Redefining Drug Delivery Platforms

Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. “Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes, and dementia, among others. These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its technology…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX